Business
Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors
LAGUNA HILLS, Calif., December 11, 2025--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company’s Audit Committee and Compensation Committee.
About this update from Adagio Medical Holdings, Inc
[{"type":"text","content":"LAGUNA HILLS, Calif., December 11, 2025--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company’s Audit Committee and Compensation Committee.","length":413,"tagName":"p"},{"type":"text","content":"Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company’s cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic’s Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Ablation, Structural Heart and Aortic, Coronary and Renal Denervation, Peripheral Vascular and Cardiac Surgery businesses. As a portfolio leader he was responsible for optimizing enterprise performance through capital allocation, talent development, strategic investments, and cross-portfolio collaboration.","length":667,"tagName":"p"},{"type":"text","content":"During his career, Mr. Salmon built extensive expertise across electrophysiology ("EP") therapies, including surgical and catheter-based ablation. He also led several strategic initiatives central to Medtronic’s growth in the EP and ablation markets, including the acquisition of Affera, the asset acquisition of Acutus’ transeptal crossing technology, and the successful CE-Mark and FDA approvals for the Pulse Select and Sphere 9 pulsed field ablation catheters, followed by their global commercialization.","length":518,"tagName":"p"},{"type":"text","content":""Adagio’s proprietary ultralow temperature ablation technology has the potential to represent a truly best-in-class innovation addressing an important unmet need for patients suffering from ventricular arrythmias," said Sean Salmon. "I believe the technology and its clinical results show significant potential to address the shortcomings of current treatments being used in the ventricle and to give physicians a unique, purpose-built solution for their patients. I am excited to be part of the future of Adagio and look forward to collaborating with the Board and management."","len...